Cardiol Therapeutics (CRDL) Projected to Post Earnings on Wednesday

Cardiol Therapeutics (NASDAQ:CRDL) will likely be announcing its Q1 2026 results after the market closes on Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.07) per share for the quarter. Investors may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Thursday, May 14, 2026 at 4:00 PM ET.

Cardiol Therapeutics (NASDAQ:CRDL) last posted its quarterly earnings results on Monday, March 30th. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.04. On average, analysts expect Cardiol Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cardiol Therapeutics Stock Down 1.5%

NASDAQ:CRDL opened at $1.31 on Wednesday. The business’s 50-day simple moving average is $1.21 and its two-hundred day simple moving average is $1.09. The stock has a market cap of $146.48 million, a PE ratio of -4.68 and a beta of 0.77. Cardiol Therapeutics has a 52 week low of $0.88 and a 52 week high of $1.71.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on CRDL shares. Canaccord Genuity Group reissued a “buy” rating and set a $8.00 price target on shares of Cardiol Therapeutics in a report on Monday, April 6th. HC Wainwright reissued a “buy” rating and set a $9.00 price target on shares of Cardiol Therapeutics in a report on Tuesday, February 10th. raised Cardiol Therapeutics to a “strong-buy” rating in a report on Tuesday, February 3rd. Finally, Wall Street Zen raised Cardiol Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, April 5th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $8.50.

Institutional Investors Weigh In On Cardiol Therapeutics

Large investors have recently made changes to their positions in the company. Security National Bank of Sioux City Iowa IA bought a new stake in shares of Cardiol Therapeutics in the fourth quarter worth about $31,000. Simplex Trading LLC increased its holdings in shares of Cardiol Therapeutics by 96.9% in the fourth quarter. Simplex Trading LLC now owns 32,197 shares of the company’s stock worth $31,000 after purchasing an additional 15,842 shares during the last quarter. Bank of America Corp DE increased its holdings in shares of Cardiol Therapeutics by 136.2% in the second quarter. Bank of America Corp DE now owns 26,455 shares of the company’s stock worth $36,000 after purchasing an additional 15,255 shares during the last quarter. Susquehanna International Group LLP increased its holdings in shares of Cardiol Therapeutics by 366.5% in the third quarter. Susquehanna International Group LLP now owns 93,398 shares of the company’s stock worth $100,000 after purchasing an additional 73,375 shares during the last quarter. Finally, Virtu Financial LLC bought a new stake in shares of Cardiol Therapeutics in the third quarter worth about $154,000. 12.49% of the stock is owned by institutional investors.

About Cardiol Therapeutics

Cardiol Therapeutics Inc (NASDAQ: CRDL) is a clinical-stage pharmaceutical company dedicated to developing immunomodulatory treatments for patients with cardiovascular disease. The company’s lead asset, CardiolRx, is a proprietary, pharmaceutical-grade cannabidiol (CBD) formulation designed to target the inflammation and oxidative stress underlying conditions such as acute myocardial injury and heart failure. Cardiol holds exclusive global rights to CardiolRx through a licensing partnership and is advancing additional preclinical programs focused on small-molecule immunotherapies for heart disease.

CardiolRx is formulated for oral administration and has been evaluated in a randomized, placebo-controlled Phase 2 myocardial protection study assessing safety and key biomarkers following acute coronary syndromes.